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representation in the sorted and unsorted cells was enumerated by high-throughput sequencing and the RNAi Gene Enrichment Ranking (RIGER) algorithm 16 was used to identify genes targeted by multiple enriched sgRNAs, representing high-confidence hits ( Supplementary  Tables 2 and 3) . A large number of established components of the miRNA pathway and miR-19 itself were identified as significant hits in HCT116 EGFP-miR19 but not HCT116 EGFP cells (Fig. 1c, d) , establishing the sensitivity of this approach.
We noted two classes of highly ranked hits without a previously defined role in the miRNA pathway: transcriptional regulators (BRD4, CTNNB1, and POU2F1) and interacting components of the serine/threonine protein phosphatase 6 (PPP6) complex (ANKRD52 and PPP6C) 17 . Loss of function of any of these genes measurably de-repressed EGFP in HCT116 EGFP-miR19 but not HCT116 EGFP cells ( Fig. 1e and Extended Data Fig. 1 ). CTNNB1 and BRD4 promote MYC expression 18, 19 , a known positive regulator of transcription of the miR-19 host transcript (pri-miR-17-92) 20 . Accordingly, analysis of MYC, pri-miR-17-92, and mature miR-19 levels in CTNNB1 -/-, BRD4 -/-, and POU2F1 -/cells provided evidence that CTNNB1 and BRD4 indirectly regulate transcription of miR-19 through MYC (Extended Data Fig. 2 ). POU2F1, in contrast, promotes pri-miR-17-92 transcription through an MYC-independent mechanism that may include interaction with a binding site in the promoter, as proposed previously 21 .
ANKRD52 and PPP6C dephosphorylate AGO2
The identification of ANKRD52 and PPP6C as significant hits suggested that phosphorylation regulates the activity of an essential miRNA pathway component. Confirming a general impairment of miRNA-mediated silencing in cells deficient for this phosphatase complex, RNA sequencing (RNA-seq) demonstrated that genes upregulated in AGO2 -/cells were similarly upregulated in ANKRD52 -/cells ( Fig. 2a , Extended Data Fig. 3 and Supplementary Table 4 ). Additional miRNA reporter constructs and endogenous let-7 targets [22] [23] [24] were also de-repressed by ANKRD52 knockout (Extended Data Fig. 4a-d) . The steady-state abundance of representative miRNAs was not decreased (Extended Data Fig. 4e ), indicating that the ANKRD52-PPP6C complex does not globally regulate miRNA biogenesis.
Owing to their central role in miRNA-mediated silencing, we hypothesized that Argonaute proteins may be dephosphorylated by ANKRD52-PPP6C. AGO2 and ANKRD52-PPP6C interacted in an RNA-independent manner (Extended Data Fig. 5a ). Phos-tag electrophoresis, a sensitive method for detection of phosphorylated proteins 25 , revealed that AGO2 migrated as a doublet, with dramatic enhancement of the slowly migrating form in ANKRD52-or PPP6Cdeficient cells (Fig. 2b) . Phosphatase treatment confirmed that the more slowly migrating species corresponded to phosphorylated AGO2 (p-AGO2; Fig. 2c ). Deficiency of ANKRD52 or PPP6C in multiple human cell lines similarly led to accumulation of phosphorylated AGO2 (Extended Data Fig. 5b ). We also observed enhanced phosphorylation of AGO1 in ANKRD52 -/cells (Extended Data Fig. 5c ), suggesting broader regulation of Argonaute proteins by the ANKRD52-PPP6C complex.
Mass spectrometry was used to identify the relevant phosphoresidue(s) in endogenous AGO2. Enhanced phosphorylation within a region of the PIWI domain containing four highly conserved serine residues and a single poorly conserved threonine residue (S824-S834) was detected in ANKRD52 -/cells, while the previously reported phosphorylation of S387 was not increased 26 (Fig. 2d and Extended Data Fig. 6a, b ). Triply phosphorylated peptides spanning S824-S834 were detected, with definitive detection of p-S824 (Extended Data Fig. 6c ). Although close spacing prevented the assignment of additional phosphorylations to specific residues, mass spectrometry using AGO2 alanine mutants allowed definitive identification of phosphorylation at S828 and S831 (Extended Data Fig. 6d, e ). Confirming these results, mutating all five serine/ threonine residues in this region to alanine (5XA) completely abolished the Phos-tag p-AGO2 band ( Fig. 2e ). Interestingly, a single S828A mutation also fully abolished the AGO2 mobility shift, suggesting that phosphorylation of this residue may be necessary to trigger hierarchical phosphorylation of additional amino acids within this region. Importantly, expression of AGO2 5XA or AGO2 S828A , but not wild-type AGO2, rescued repression of the miR-19 EGFP reporter in ANKRD52 -/cells ( Fig. 2f ), demonstrating that the defect in miRNA-mediated silencing caused by loss of ANKRD52 was specifically due to hyperphosphorylation of AGO2 at S824-S834. 
Phosphorylation inhibits target binding
AGO2 S824-S834 is within a structurally unresolved loop of the PIWI domain that is located in the vicinity of the miRNA:target interface 27, 28 .
We therefore hypothesized that phosphorylation in this region may reduce miRNA and/or target association. Immunopurification of endogenous AGO2 from ANKRD52 +/+ or ANKRD52 -/cells demonstrated equivalent miRNA association ( Fig. 3a) . In contrast, AGO2 target association was significantly reduced in ANKRD52 -/cells, as determined by assessing AGO2 binding to the miR-19 EGFP reporter transcript and two established targets of miR-16 or let-7 ( Fig. 3b ) 22, 23, 29 .
To confirm these findings, AGO2:miRNA complexes were captured with an RNA oligonucleotide that mimics a target of miR-21, an abundant miRNA in HCT116 cells 30, 31 (Fig. 3c ). Whereas unphosphorylated AGO2 was efficiently recovered using this approach, binding of phosphorylated AGO2 to the synthetic target was dramatically decreased ( Fig. 3d ). Importantly, both phosphorylated and unphosphorylated forms of AGO2 were efficiently recovered by immunoprecipitation using an anti-AGO2 antibody, demonstrating that the relevant phosphoresidues were stable under these conditions. A series of phosphomimetic mutants were generated to identify the specific phosphoresidues that impair AGO2 target association (Extended Data Fig. 7a ). As expected, none of the mutations measurably decreased miRNA association (Extended Data Fig. 7b ). In contrast, target association was significantly impaired by mutation of all five serine and threonine residues in the S824-S834 region to glutamic acid (5XE) and, more importantly, individual mutations or combinations of mutations that mimic definitive phosphorylation sites documented by mass spectrometry (S831E, S828E/S831E, and S824E/S828E/S831E) ( Fig. 3e ). Notably, mutation of S828 or all serines and threonines in this region to alanine (S828A or 5XA, respectively) did not inhibit target interaction. Consistent with an isolated effect of S824-S834 phosphorylation on target binding, tethering AGO2 WT , AGO2 5XE , or AGO2 5XA to a luciferase transcript using the λN peptide-boxB system 32 resulted in equivalent repression ( Fig. 3f ). Taken together, these findings establish that phosphorylation of S824-S834 potently and specifically inhibits AGO2:target interactions.
CSNK1A1 is the inhibitory AGO2 kinase
We next sought to identify the kinase that initiates this inhibitory mechanism. Reasoning that loss of function of the kinase would rescue miRNA-mediated silencing in the ANKRD52-deficient state, we performed a secondary genome-wide CRISPR-Cas9 screen in ANKRD52 -/-HCT116 EGFP-miR19 cells and collected the dimmest 0.5% of cells ( Fig. 4a ). RIGER analysis revealed four serine/threonine kinases among the top 100 hits: LATS2, CSNK1A1, MTOR, and SRPK1 ( Fig. 4b and Supplementary Table 5 ). Knockout of LATS2 or SRPK1 in the ANKRD52 -/background resulted in minimal to no recovery of EGFP repression (Extended Data Fig. 8a, b ). mTOR knockout or inhibition with rapamycin moderately rescued EGFP repression but did not influence AGO2 phosphorylation (Extended Data Fig. 8a , c, d). In stark contrast, knockout of CSNK1A1 in ANKRD52 -/cells (Extended Data Fig. 9a ) fully rescued repression of the EGFP reporter without increasing miR-19 levels ( Fig. 4c and Extended Data Fig. 9b ), greatly reduced AGO2 phosphorylation (Fig. 4d ), and restored AGO2 target association ( Fig. 4e ).
Co-immunoprecipitation demonstrated an RNA-independent interaction between CSNK1A1 and AGO2 (Extended Data Fig. 9c ). Moreover, the casein kinase I family, of which CSNK1A1 is a member, prefers previously phosphorylated substrates conforming to the consensus (pS/pT/D/E)-X 1-2 -S/T, with the latter S/T representing the phospho-acceptor site 33, 34 . The five serine/threonine residues within AGO2 S824-S834 all conform to this consensus motif, with S824 and S828 preceded by acidic residues and T830, S831, and S834 having the potential to be primed by hierarchical phosphorylation initiating at S828. Phosphorylation of full-length wild-type AGO2 but not AGO2 5XA by recombinant CSNK1A1 was robustly detectable in vitro, with or without pre-treatment with phosphatase to remove potential priming phosphorylations ( Fig. 4f ). To investigate potential hierarchical phosphorylation of these residues, CSNK1A1 kinase assays were performed with a series of phospho-peptides encompassing amino acids 824-834 of AGO2 ( Fig. 4g ). Unphosphorylated peptide was a poor substrate for CSNK1A1 under these conditions, suggesting that initial phosphorylation of this region is facilitated by contextual features present in full-length AGO2. pS824 only weakly stimulated further phosphorylation. Prior phosphorylation of S828, however, robustly promoted phosphorylation of S831 (but not T830), while pS831 efficiently primed phosphorylation of S834. Taken together with our earlier data demonstrating a critical role for S828 in phosphorylation of AGO2 in cells ( Fig. 2e ), these findings support a model whereby initial phosphorylation of S828, and potentially S824, stimulates efficient hierarchical phosphorylation of S831 followed by S834, rendering AGO2 incompetent for target binding until returned to an active state by ANKRD52-PPP6C phosphatase activity.
Target binding triggers phosphorylation
Although deficiency of AGO2 S824-S834 phosphorylation was compatible with fully efficient silencing of the miR-19 EGFP reporter ( Fig. 4c ), RNA-seq revealed that genes that are upregulated in AGO2 -/cells were similarly upregulated in CSNK1A1 -/-;ANKRD52 -/double knockout cells ( Fig. 5a and Supplementary Table 4 ). These findings suggested that AGO2 S824-S834 phosphorylation is necessary for efficient silencing of endogenous miRNA targets. Further supporting this conclusion, AGO2 -/cells stably reconstituted with AGO2 5XA exhibited a highly significant defect in miRNA-mediated repression compared with cells reconstituted with AGO2 WT (Fig. 5b , Extended Data Fig. 10a and Supplementary Table 6 ).
Given that this newly described AGO2 phosphorylation cycle is constitutively active in mammalian cell lines, is necessary to maintain the efficiency of miRNA-mediated silencing, and regulates target binding, we postulated that S824-S834 phosphorylation may be triggered by target engagement itself. To test this hypothesis, we first generated AGO2 mutants with an isolated deficiency in target binding, guided by the structure of AGO2 in complex with a miRNA and target 35 . Two mutations, R438E and K525E, dramatically reduced target binding without affecting miRNA association, while a third mutation, D358K, partly inhibited both target binding and miRNA association ( Fig. 5c and Extended Data Fig. 9d ). Phosphorylation of AGO2 R438E and AGO2 K525E , but not AGO2 D358K , was strongly impaired ( Fig. 5d ), consistent with a role for target binding in facilitating AGO2 phosphorylation.
To directly test whether engagement of a target can trigger AGO2 phosphorylation, HCT116 cells were transfected with constructs expressing circular or linear forms of circular RNA sponge for miR-7 (ciRS-7), a previously described transcript with over 70 binding sites for miR-7 (ref. 36) . Expression of these transcripts along with miR-7, which is not normally expressed in HCT116 cells, was sufficient to trigger robust AGO2 phosphorylation in a CSNK1A1-dependent manner ( Fig. 5e ). These findings demonstrate that target engagement is a strong trigger for AGO2 S824-S834 phosphorylation.
Phosphorylation remodels AGO2 targeting
Lastly, to investigate why loss of AGO2 S824-S834 phosphorylation impairs miRNA-mediated silencing, we examined the transcriptome-wide target binding profiles of AGO2 WT and AGO2 5XA using enhanced crosslinking immunoprecipitation (eCLIP) 37 . Whereas both AGO2 WT and AGO2 5XA bound primarily to sites within mRNA 3′ UTRs ( Fig. 6a , Extended Data Fig. 10b and Supplementary Table 7 ), AGO2 5XA had more than twice as many detectable binding sites (2,921 CLIP clusters for AGO2 5XA versus 1,190 clusters for AGO2 WT ). Streptavidin beads While this corresponded to more than twice as many genes bound by AGO2 5XA , virtually all genes bound by AGO2 WT were also bound by AGO2 5XA (Fig. 6b ). Thus, loss of AGO2 S824-S834 phosphorylation dramatically expands the target repertoire bound by AGO2 at steadystate. AGO2 immunoprecipitation confirmed enhanced binding of AGO2 5XA to representative targets identified by CLIP (Extended Data Fig. 10c ).
A significant expansion of binding sites would be expected to reduce the pool of AGO2 5XA that is available to interact with and silence any given individual target transcript. Indeed, targets of wild-type AGO2 with 8-, 7-, or 6-nucleotide miRNA seed complementarity showed reduced binding by AGO2 5XA (Fig. 6c ). This finding offers a plausible explanation for the global defect in miRNA-mediated silencing observed in AGO2 5XA -reconstituted cells ( Fig. 5b ). Nevertheless, silencing of some transcripts, including the miR-19 EGFP reporter, was not impaired by loss of AGO2 S824-S834 phosphorylation ( Fig. 4c ). We speculated that transcripts that are efficiently repressed by AGO2 5XA represent particularly strong targets that are able to compete effectively for AGO2 binding against the expanded AGO2 5XA target pool. Consistent with this hypothesis, genes whose repression was rescued by expression of AGO2 5XA in AGO2 -/cells exhibited greater wild-type AGO2 CLIP coverage (Extended Data Fig. 10d ), indicating that they are stronger miRNA targets.
Finally, we sought to identify features of transcripts that are preferentially bound by AGO2 5XA . Interestingly, the frequency of AGO2 5XA crosslinking to seed matches was equivalent between clusters uniquely identified by AGO2 5XA CLIP and clusters that were common to AGO2 WT and AGO2 5XA (Extended Data Fig. 10e ). This suggested that the additional sites identified by AGO2 5XA CLIP are bona fide miRNA binding sites that are uniquely detected owing to a prolonged AGO2:target interaction that occurs in the absence of the phosphorylation cycle. In light of this, we reasoned that transcript half-life may influence the relative binding of AGO2 5XA versus AGO2 WT , since association with slowly decayed transcripts would provide greater opportunity for AGO phosphorylation relative to transcripts that are rapidly decayed. Transcripts bound by AGO2 5XA were classified on the basis of published transcriptome-wide half-life measurements 38 . Indeed, transcripts with long half-lives exhibited greater binding by AGO2 5XA relative to AGO2 WT than transcripts with short half-lives (Extended Data Fig. 10f ).
Discussion
This study describes the application of genome-wide CRISPR-Cas9 screening coupled with a fluorescent reporter to interrogate the miRNA pathway. An in-depth analysis of the ANKRD52-PPP6C phosphatase complex, identified as a major regulator of the miRNA pathway through this approach, unexpectedly reveals that continual transient phosphorylation of AGO2 is required to maintain the global efficiency of miRNA-mediated repression. Our experiments demonstrate that target engagement by AGO2 stimulates its hierarchical, multi-site phosphorylation by CSNK1A1 on a series of highly conserved residues (S824-S834) (Extended Data Fig. 10g ). Although this impairs target binding, dephosphorylation by ANKRD52-PPP6C allows AGO2 to engage new targets. Inactivation of this cycle strongly inhibits global miRNA-mediated repression.
Given that AGO2 S824-S834 phosphorylation impairs target association, why is continual phosphorylation/dephosphorylation of these residues necessary for efficient miRNA activity? Transcriptomewide analyses of AGO2 targets suggest that this silencing defect is attributable to a dramatic expansion of the target repertoire bound by non-phosphorylatable AGO2 at steady-state, effectively reducing the pool of active AGO2 on a per-target basis. Multiple potential mechanisms may contribute to this effect. First, it is possible that AGO:target interactions are much more stable in vivo than suggested by in vitro measurements 8, 9 . In this case, AGO could potentially persist on a target longer than is necessary to trigger a productive silencing interaction. Given that target levels greatly exceed miRNA levels in mammalian cells 6, 7 , active disassembly of AGO:target complexes via S824-S834 phosphorylation would thereby effectively increase AGO availability to silence additional targets. Structural studies have revealed AGO2 conformational changes induced by target engagement 35 . While S824-S834 are unresolved in existing AGO structures, it is possible that target binding exposes these sites to the activity of CSNK1A1, providing a timing mechanism that limits the duration of target interaction. This model is consistent with our finding of enriched binding of non-phosphorylatable AGO2 to transcripts with long half-lives since the stable association of AGO2 with slowly decayed transcripts would provide a greater opportunity for CSNK1A1 phosphorylation relative to mRNA targets that are rapidly degraded. AGO phosphorylation might be further stimulated by the successful recruitment of additional silencing factors such as the CCR4-NOT deadenylase complex and/or DDX6, indicating the completion of a productive silencing interaction. An alternative, non-mutually exclusive model to account for greater association of AGO2 5XA with specific targets posits the existence of additional features, such as sites for RNA binding proteins, that promote AGO phosphorylation, thus actively disfavouring stable AGO association. This would effectively focus AGO activity on a subset of the possible targets in a cell, facilitating their productive repression. Further characterization of the distinguishing features of targets that most efficiently promote AGO2 phosphorylation will help resolve these uncertainties.
In the context of these models, the conservation pattern of these phosphorylation sites may be informative. In particular, while the relevant serines are conserved in Drosophila AGO1 (Fig. 2d ), which carries out miRNA-mediated repression, these sites are absent in Drosophila AGO2, which performs siRNA-mediated target slicing. Single-molecule studies have documented accelerated AGO dissociation following target cleavage 8, 9 , potentially obviating the need for phosphorylation to facilitate Drosophila AGO2 target disengagement. On the other hand, the deep evolutionarily conservation of these phosphorylation sites in Argonaute proteins that perform miRNA-mediated repression strongly suggests that this phosphorylation cycle is a broadly used mechanism to optimize miRNA activity in diverse species. In addition, the potent inhibitory effect of S824-S834 phosphorylation would provide a powerful mechanism to regulate the global activity of the miRNA pathway by upstream signalling pathways. This possibility highlights the importance of future studies to examine this newly discovered Argonaute phosphorylation cycle in diverse developmental, physiological, and pathophysiological contexts.
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MethOdS
No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Cell culture. Cell lines used in this study were obtained from American Type Culture Collection (ATCC) and cultured under standard conditions. HCT116 cells were authenticated by karyotyping. All cell lines were confirmed to be free of mycoplasma contamination. Construction of EGFP miRNA reporters. EGFP was PCR amplified from EGFP-hAGO2 (Addgene catalogue number 21981) and cloned into pMSCV-Puro (Clontech) using the BglII and XhoI restriction sites. The puromycin resistance cassette was then removed by EcoRI and ClaI digestion and replaced with an insert containing eight imperfect miR-19 binding sites (modelled from ref. 39 ), synthesized as a gBlock (IDT) (sequence in Supplementary Table 8 ). For the EGFP-only reporter, the puromycin resistance cassette was removed by EcoRI and ClaI digestion followed by re-ligation after filling-in overhangs.
Reporters for miR-16 and miR-200c were generated by replacing the puromycin cassette in the pMSCV-Puro vector containing EGFP by digesting with EcoRI and ClaI and ligating in oligonucleotides containing single miRNA binding sites (sequences in Supplementary Table 8 ). Multiple cloning cycles were performed using MfeI and ClaI to generate the final reporters containing eight total binding sites. Generation of HCT116 reporter cell lines. MSCV-EGFP, MSCV-EGFP-miR-19, MSCV-EGFP-miR-16, and MSCV-EGFP-miR-200 retrovirus was generated by first seeding 6 × 10 5 cells per well in a six-well dish. The following day, cells were transfected using 1 μg of plasmid (MSCV-EGFP or MSCV-EGFP-miR-19), 3 μl of FuGENE HD (Promega), and 200 μl Opti-MEM (Thermo Fisher) per well according to the manufacturer's instructions. Media were changed the next day. Two days after transfection, media were collected and passed through a 0.45 μm SFCA sterile filter. Recipient HCT116 cells were transduced overnight at a multiplicity of infection (MOI) of approximately 0.2 using media supplemented with 8 μg/ml polybrene (EMD Millipore). Cells expressing EGFP were enriched by FACS and single-cell clonal lines were derived. Generation of knockout cell lines using CRISPR-Cas9. Heterogeneous knockout cell populations were generated using lentiCRISPR v2 (Addgene catalogue number 52961) or lentiCRISPR-hygro. lentiCRISPR-hygro was constructed by replacing the puromycin resistance open reading frame (ORF) in lentiCRISPR v2 with a hygromycin resistance ORF. A silent mutation was introduced into a BsmBI restriction site within the hygromycin resistance ORF to prevent fragmentation of the vector when cloning sgRNA oligonucleotides. sgRNA sequences ( Supplementary Table  8 ) were cloned as described previously 12 . An sgRNA targeting an irrelevant gene (PPID) or a non-targeting guide were used as negative controls.
To generate active lentivirus, 6 × 10 5 293T cells were first seeded in six-well dishes and transfected the following day using a 5:3:2 ratio of lentiCRISPR:psPAX2 (Addgene catalogue number 12260):pMD2.G (Addgene catalogue number 12259) using FuGENE HD and 1 μg of total plasmid per well. Media were changed the next day. Two days after transfection, media were collected and passed through a 0.45 μm SFCA sterile filter. Media containing the virus were diluted 1:1 with fresh media and used to transduce recipient cells overnight in a final polybrene concentration of 8 μg/ml. Media were changed 24 h later, and cells were split into fresh media containing 1 μg/ml puromycin 48 h after transduction.
To The human GeCKO v2 library was obtained from Addgene (catalogue number 1000000048) and amplified according to the provided instructions. Plasmid was purified from bacterial pellets using a Qiagen Plasmid Maxi Kit. Active lentivirus was prepared in 293T cells by first seeding 3.2 × 10 6 cells per 10-cm dish. GeCKO library A and library B were prepared independently using 15 dishes per library. The day after seeding, each dish was transfected using 10 μg of total plasmid (5:3:2 ratio of GeCKO library:psPAX2:pMD2.G), 30 μl of FuGENE HD, and 900 μl of Opti-MEM. Medium was exchanged the following day. Media collections at 48 and 72 h after transfection were pooled before filtering through a 0.45 μm SFCA sterile filter. Aliquots of the library were snap frozen on dry ice and ethanol before being stored at −80 °C. Library titre was determined as described 12 . Transduction of reporter cell lines with lentiCRISPR library. Genome-wide CRISPR-Cas9 screens using HCT116 EGFP-miR-19 , HCT116 EGFP , or ANKRD52 -/-HCT116 EGFP-miR-19 cells were performed using both GeCKO v2 libraries A and B. Biological replicates were performed for all screens. For each transduction, five 12-well plates were seeded with 5 × 10 5 reporter cells per well. An overnight transduction was performed the following day by diluting virus to an MOI of 0.2-0.4 in 8 μg/ml polybrene. Cells were then trypsinized and pooled before being plated into fresh medium in six 15-cm dishes. Forty-eight hours later, cells were trypsinized, pooled, counted, and seeded into five 15-cm dishes with 1 μg/ml puromycin using 2.4 × 10 7 cells per dish. In parallel, a small aliquot of cells was used to confirm that an MOI of 0.2-0.4 was achieved. Cells were passaged for 12-14 days before sorting. At every passage, 1 × 10 7 cells were seeded per dish into four 15-cm dishes with medium containing puromycin. At least 2 × 10 7 cells were transduced with each library for each screen, corresponding to ~300× or greater coverage. Cell sorting. Two days before sorting, ten 15-cm dishes with 1.2 × 10 7 cells per dish were seeded for each library-reporter pair. Samples were prepared for FACS by trypsinization in 0.25% trypsin-EDTA (Thermo Fisher) for 7 min. Cells were dissociated by pipetting up and down approximately 20 times with a P1000 pipet to minimize doublets. Dissociated cells were pipetted directly into media, pelleted at 300g for 5 min, and washed once with PBS. Cells were resuspended at 1.4 × 10 7 cells per millilitre in PBS supplemented with 3% FBS. Cells were sorted at the University of Texas Southwestern Flow Cytometry Core Facility using a MoFlo cell sorter (Beckman Coulter). The brightest or dimmest 0.5% of cells were collected on the basis of EGFP fluorescence. Cell sorting was performed on approximately 9 × 10 7 cells, and typical yields ranged from 2 × 10 5 to 3 × 10 5 sorted bright/dim cells. Cells were pelleted at 300g and frozen at −80 °C for genomic DNA (gDNA) extraction. Unsorted cells were similarly collected. Genomic DNA extraction. gDNA was extracted from the unsorted cells using a Qiagen DNeasy Blood & Tissue Kit according to the manufacturer's instructions. Extractions were performed on 4 × 10 7 cells using 5 × 10 6 cells per column to ensure enough gDNA for 300× coverage of the library. DNA was eluted by adding 125 μl of water to each column. The same eluate was added back to the column for a second elution. The DNA concentration in the final eluate was assessed using a Qubit dsDNA BR assay kit (Thermo Fisher).
To facilitate maximum recovery of gDNA from the sorted cells, a previously described method 40 was used with the following modifications: sorted cell pellets were resuspended in 500 μl of tissue lysis buffer, consisting of 460 μl of STE buffer (1 mM EDTA (pH 8.0), 10 mM Tris-HCl (pH 8.0), 100 mM NaCl) supplemented with 10 μl of 0.5 M EDTA, 10 μl of proteinase K (10 mg/ml in TE buffer containing 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA), and 20 μl of 10% SDS. Pellets were digested overnight at 55 °C while shaking at 1,000 r.p.m. on a Thermomixer (Eppendorf). The following day, 5 μl of 2 mg/ml RNase A was added to each tube and incubated at 37 °C for 1 h while shaking at 1,000 r.p.m. Extractions were performed with an equal volume of pH 7.9-buffer saturated phenol, followed by phenol:chloroform:isoamyl alcohol (25:24:1), followed by chloroform. Twenty micrograms of glycogen (Roche) and 1.5 ml of 100% ethanol were added to each tube and DNA was precipitated at −80 °C for 1 h followed by centrifugation at 18,000g for 10 min at 4 °C. Pellets were washed with 1 ml of 75% ethanol, dried, and resuspended in 21 μl of water by incubating at 37 °C for a minimum of 4 h. DNA concentration was determined with the Qubit dsDNA BR assay kit. Sequencing library preparation. Methods to prepare PCR amplicon libraries for deep sequencing were adapted from a previously published protocol 12 . All primer sequences are provided in Supplementary Table 8 . For unsorted cells, an initial round of PCR (PCR I) was performed using 6.6 μg of gDNA per 100 μl PCR reaction. To maintain 300× coverage, 20 reactions were assembled for each sample. For sorted cells, all extracted gDNA for a given sample was distributed into two 100 μl reactions. In both cases, 18 cycles of amplification were performed using Herculase II Fusion polymerase (Agilent). All reactions for a given sample from PCR I were then pooled together and a second round of PCR (PCR II) was performed to add the necessary adapters for Illumina sequencing. Owing to variable PCR efficiency between samples, the cycle number for PCR II was adjusted so that each library was amplified in a 50 μl reaction to a common endpoint with respect to DNA quantity (approximately 50 ng of DNA library in a 50 μl PCR sample).
DNA was purified for sequencing using AMPure XP beads (Agencourt) according to the manufacturer's instructions with the following modifications: each 50 μl PCR II reaction was mixed with 25 μl of beads and incubated for 5 min. Magnetic separation was used to collect the supernatant. The supernatant was mixed with 90 μl of beads and incubated for 5 min. The supernatant was collected and Article reSeArcH discarded. Beads were washed twice with 200 μl of 70% ethanol and then dried for approximately 12 min. Bound DNA was eluted from the beads using 40 μl of water. Next-generation sequencing. Before sequencing, all DNA libraries were analysed using a Bioanalyzer High Sensitivity DNA Analysis Kit (Agilent). Library concentration was then determined by qPCR using a KAPA Library Quantification Kit for Illumina platforms. All samples were sequenced on an Illumina HiSeq 2500 or a NextSeq 500 with 75 bp single reads. Approximately 15 million to 20 million reads were sequenced per library. Sequencing data analysis. A reference file for all sgRNAs in the library was acquired from Addgene, and identical sgRNAs targeting more than one protein-coding gene were removed. Demultiplexed FASTQ files were mapped to the reference file using Bowtie 2 requiring unique alignments with no mismatches. Normalized read counts were calculated as described previously 12 . Screen hits were identified using RIGER 16 with the following parameters: log(fold-change ranking), 1 × 10 6 permutations, second-best rank (SBR) scoring algorithm. qRT-PCR. RNA was extracted from cells using a miRNeasy Mini Kit (Qiagen) with an on-column DNase digestion. cDNA was generated using either the SuperScript IV First-Strand Synthesis System (Thermo Fisher) or MultiScribe Reverse Transcriptase (Thermo Fisher). SYBR Green assays were performed using SYBR Green PCR Master Mix (Applied Biosystems) with custom primer pairs or qRT-PCR assays for mature miRNAs or mRNAs were performed using predesigned assays and the TaqMan Universal Master Mix II (Applied Biosystems). Primer sequences and catalogue numbers provided in Supplementary Table 8 . A custom Taqman assay was designed for pri-miR-17-92 (sequences provided in Supplementary Table 8 ). Co-immunoprecipitation assays. For all co-immunoprecipitation assays, 3.2 × 10 6 293T cells were seeded 1 day before transfection. Cells were transfected using FuGENE HD with 10 μg of total plasmid. Media were changed the following day. Cells were harvested 48 h after transfection. Cells were washed once, scraped in PBS, and lysed on ice for 10 min in 1 ml of lysis buffer composed of 25 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM MgCl 2 , 0.5% NP-40, 1 mM DTT, and a protease inhibitor cocktail (cOmplete EDTA-free, Roche). Lysates were spun at 10,000g for 10 min. Supernatants were collected and diluted with 0.5 volumes of fresh lysis buffer. One and a half microlitres of immunoprecipitation antibody (anti-V5 (Invitrogen catalogue number 46-0705) or anti-HA (Cell Signaling catalogue number 2367S)) were added to each sample and rotated at 4 °C for 30 min. Thirty microlitres of washed Dynabeads Protein G (Thermo Fisher) were added to each sample and incubated for 6 h. RNase A (Thermo Fisher) was added to a final concentration of 20 μg/ml where indicated. Samples were washed four times in ice-cold lysis buffer. Fifty microlitres of 2× Laemmli sample buffer were added to each sample and aliquots were used for western blot analysis. Western blot antibodies. Antibodies used for western blotting included anti-HA (2367S, Cell Signaling), anti-V5 (46-0705, Invitrogen), anti-AGO2 (SAB4200085, Sigma), anti-GAPDH (2118S, Cell Signaling), anti-α-tubulin (T6199-200UL, Sigma), anti-BRD4 (13440S, Cell Signaling), anti-CTNNB1 (9587S, Cell Signaling), anti-POU2F1 (8157S, Cell Signaling), anti-ANKRD52 (A302-372A, Bethyl), and anti-CSNK1A1 (sc-6477, Santa Cruz). Phos-tag SDS-PAGE electrophoresis. SDS-PAGE gels (7%) were supplemented with Phos-tag AAL solution (Wako) according to the manufacturer's recommendations. Gels were run at 100 V in an XCELL SureLOCK Mini-Cell (Invitrogen) until the dye front completely exited the gel. Gels were incubated in transfer buffer supplemented with 1 mM EDTA for 10 min. Gels were then soaked in normal transfer buffer for 10 min. Proteins were transferred to a nitrocellulose membrane and standard western blotting procedures were subsequently followed.
For lambda phosphatase treatments, lysates were generated as described in the co-immunoprecipitation assays. Lysate (50 μl) was mixed with 10× MnCl 2 buffer and 10× reaction buffer provided with the lambda protein phosphatase kit (NEB). Samples treated with enzyme received 1 μl of purified lambda protein phosphatase. Incubations were performed for 45 min at 30 °C, and samples were subjected to chloroform-methanol precipitation 41 before Phos-tag electrophoresis. Mass spectrometry. Endogenous AGO2 was purified from ANKRD52 +/+ and ANKRD52 -/-HCT116 cells. AGO2 -/cells were used as a control. Ten million cells were seeded per 15-cm dish, and eight dishes were used per cell line. AGO2 was immunoprecipitated using methods adapted from an established protocol 42 with 100 μl of Dynabeads Protein G loaded with 18 μg of anti-AGO2 antibody (SAB4200085, Sigma) per purification. Immunoprecipitation eluates were resuspended in 5× Laemmli sample buffer.
FH-AGO2 constructs (WT, T830A, S824A/T830A) were stably expressed using MSCV-puro in ANKRD52 -/cells. Ten million cells were seeded per 15-cm dish, and eight dishes were used per cell line. Media were changed 48 h later. Cells were scraped in PBS 72 h after plating. Lysates were generated using methods similar to the co-immunoprecipitation assays, with the exception that a phosphatase inhibitor cocktail (PhosStop, Roche) was included and lysate supernatants were diluted with one volume of lysis buffer. Proteins were immunoprecipitated using 100 μl of Dynabeads Protein G loaded with 20 μg of anti-Flag antibody (F1804, Sigma). Beads were rotated at 4 °C for 3 h. Beads were washed five times in lysis buffer. Proteins were eluted using 70 μl of 2× Laemmli sample buffer per 100 μl of beads.
Purified AGO2 proteins were separated by SDS-PAGE and stained using InstantBlue (Expedeon). Gel slices containing AGO2 bands were reduced by DTT, alkylated by iodoacetic acid, and digested with trypsin (Trypsin Gold; Promega). The digestion was stopped by adding formic acid, followed by peptide extraction in acetonitrile. Extracted peptides were desalted by C18 ZipTip (Millipore).
Peptide mixtures were separated by C-18 resin (100 Å, 3 μm, MICHROM Bioresources) in-house packed into a silica capillary emitter (100 μm ID, 100 mm resin length). LC gradient was generated by a Dionex Ultimate 3000 nanoLC system (Thermo Scientific), with mobile phase A: 0.1% formic acid and B: 0.1% formic acid in acetonitrile. Mobile phase gradient: 2% B at 0-15 min, 30% B at 81 min, 35% B at 85 min, 40% B at 87 min, 60% B at 95 min, 80% B at 96-107 min and 2% B at 108-120 min. Flow rate: 600 nl/min at 0-13.5 min, 250 nl/min at 13.5-120 min.
Peptide eluents were sprayed online with a nano-electrospray ion source (Thermo Scientific) at spray voltage of 1.5 kV and capillary temperature of 250 °C. High-resolution MS analysis was performed on a QExactive Quadrupole-Orbitrap Hybrid mass spectrometer (Thermo Scientific), operating in data-dependent mode with dynamic exclusion of 30 s. Full-scan MS was acquired at an m/z range of 300-1650, resolution of 70,000, and automatic gain control target of 3 × 10 6 ions. The top 15 most intense ions were subsequently selected for higher-energy collisional dissociation fragmentation at resolution of 17,500, collision energy of 27 eV, and automatic gain control target of 1 × 10 5 ions.
Proteome data analysis used Mascot (Matrix Science) and Proteome Discoverer (1.4, Thermo Scientific). The raw data were searched against the human proteome database (Uniprot, UP000005640) plus common contaminants. Static modification was cysteine carbamidomethylation; variable modifications were serine or threonine phosphorylation, methionine oxidation, and glutamine or asparagine deamination. Precursor mass tolerance was 20 p.p.m. and fragment mass tolerance, 0.05 Da. The maximum number of miscleavage sites allowed was 2. After peptide identification, precursor ion intensities were quantified manually in XCalibur using extracted ion chromatogram. Cloning, mutagenesis, and expression of cDNA constructs. Sequences of all primers used for cloning are provided in Supplementary Table 8 . Flag-HA-AGO2 (FH-AGO2) was PCR amplified from pIRES-neo-Flag/HA AGO2 (Addgene catalogue number 10822) and subcloned into pcDNA3.1+. FH-AGO2 mutants were generated using a QuikChange II XL Site-Directed Mutagenesis Kit (Agilent) or by cloning customized gBlocks (IDT) into the parental pcDNA3.1+ vector containing FH-AGO2 (sequence of all mutants provided in Supplementary Table 8 ). Stable expression of wild-type or mutant FH-AGO2 was achieved in one of two ways. In one, constructs were subcloned into pMSCV-puro (Clontech). In another, stable expression of AGO2 for RNA-seq and eCLIP experiments was achieved by cloning individual mutants into a modified pLJM1-EGFP vector (Addgene catalogue number 19319) where EGFP was resected using AgeI and BsrGI before blunt-end ligation. AGO2 constructs were introduced at the EcoRI cloning site. Flag-HA-AGO1 was subcloned from pIRESneo-Flag/HA AGO1 (Addgene catalogue number 10820) into pMSCV-PIG (Addgene catalogue number 21654). V5-tagged ANKRD52 (corresponding to NP_775866.2) was constructed by PCR amplification from HCT116 cDNA followed by cloning into pcDNA3.1+. cDNA clones for human PPP6C and CSNK1A1 were obtained from the Invitrogen Ultimate ORF LITE Library (Clone ID IOH7224 and IOH59150, respectively) and subcloned into pCAGIG (Addgene catalogue number 11159) using Gateway LR Clonase (Thermo Fisher). For tethering assays, a 5× BoxB sequence adapted from a previous report 32 was designed as a gBlock (IDT) and cloned in the XbaI site of pGL3-Control (Promega) (sequence in Supplementary Table 8 ). For the λN constructs, a gBlock containing the λN peptide sequence with an HA tag 32 was subcloned into pcDNA3.1-FH-AGO2, replacing the Flag-HA tag. To generate control plasmid expressing λN-HA peptide alone, the λN-HA sequence was PCR amplified and cloned into pcDNA3.1+.
Expression of FH-AGO2 mutants in ANKRD52 -/-HCT116 EGFP-miR-19 cells.
Active lentivirus was generated using FH-AGO2 mutants (WT, 5XA, S828A, and empty vector) cloned into a modified pLJM1 vector with EGFP resected. A viral packaging protocol analogous to that used for the lentiCRISPR lentivirus preparations was used. Recipient ANKRD52 -/-HCT116 EGFP-miR-19 cells were transduced at an MOI of approximately 0.2. Transduced cells were selected in puromycin for at least 10 days, before use in flow cytometry experiments (Fig. 2f) . AGO2:miRNA and AGO2:mRNA association studies. For experiments involving endogenous AGO2, HCT116 EGFP-miR-19 cells were used. For analysis of FH-AGO2 miRNA or mRNA binding, cells stably expressing the indicated wild-type or mutant FH-AGO2 protein were first generated by infecting AGO2 -/-HCT116 cells with MSCV retroviruses. Then, for each immunoprecipitation sample, 6 × 10 6 cells were seeded per 10-cm dish. Cells were harvested 48 h later by scraping in PBS. Pelleted cells were resuspended in 1 ml of a lysis buffer consisting of 25 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM MgCl 2 , 0.5% NP-40, 1 mM DTT, a protease inhibitor cocktail (cOmplete, EDTA-free, Roche), and 250 U/ml Recombinant RNasin Ribonuclease Inhibitor (Promega). Cells were lysed on ice for 10 min. Samples were spun at 10,000g for 10 min. Supernatant fractions were retained. Protein concentration was determined using a Bio-Rad DC Protein Assay Kit, and all samples were adjusted to the same concentration with lysis buffer. Dynabeads Protein G (Thermo Fisher) were prepared by pre-incubating with 1.5 μg of antibody (either anti-Flag (F1804, Sigma) or anti-AGO2 (SAB4200085, Sigma)) and pre-blocking with 0.5 mg/ml BSA, 0.5 mg/ml yeast tRNA, and 0.2 mg/ml heparin. Each sample was incubated with 25 μl of prepared Dynabeads Protein G for 3 h at 4 °C. Samples were washed three times in lysis buffer. Captured protein was eluted from the beads using either 2.5 mg/ml 3× Flag peptide (Sigma) or 3.5 mg/ml AGO2 peptide (sequence derived from ref. 42 , synthesized at the University of Texas Southwestern Protein Chemistry Technology Core) dissolved in lysis buffer. Eighty per cent of the eluate was harvested for RNA extraction and 20% was diluted with 2× Laemmli sample buffer for western blot analysis. For each immunoprecipitation, qRT-PCR assays were performed to determine input and immunoprecipitation levels for mature miRNAs and mRNA targets of interest. Western blot analysis determined the relative amount of AGO2 in the immunoprecipitation eluate. RNA quantity as a percentage of input was determined for all immunoprecipitation eluates and then normalized to the relative amount of protein captured in each eluate. AGO2 capture using an mRNA target mimic. Experiments to capture AGO2 loaded with miRNA were adapted from a previously published method 30 . ANKRD52 +/+ and ANKRD52 -/-HCT116 EGFP-miR-19 cells were seeded at 1.35 × 10 7 cells per dish in six 15-cm dishes per cell line. Forty-eight hours later, cells from each dish were scraped in PBS, pelleted, and lysed on ice for 10 min in 1 ml of a buffer containing 25 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM MgCl 2 , 0.5% NP-40, 1 mM DTT, a protease inhibitor cocktail (cOmplete, EDTA-free, Roche), a phosphatase inhibitor cocktail (PhosStop, Roche), and 250 U/ml Recombinant RNasin Ribonuclease Inhibitor (Promega). Lysates were spun at 10,000g for 10 min and supernatants were further diluted with one volume of lysis buffer. To assess binding of AGO2 to the target mimic, 1.8 ml of each lysate was incubated with 50 μl of washed Dynabeads MyOne Streptavidin C1 (Thermo Fisher) pre-loaded with 300 pmol of wild-type or mutant RNA oligonucleotide ( Supplementary Table  8 ) and pre-blocked with 1 mg/ml BSA, 0.5 mg/ml yeast tRNA, and 0.2 mg/ml heparin. To assess AGO2 phosphorylation after immunoprecipitation, 1.8 ml of each lysate was incubated with 50 μl of washed Dynabeads Protein G (Thermo Fisher) pre-incubated with 5 μl of anti-AGO2 antibody (SAB4200085, Sigma 42 ) and pre-blocked as noted previously. Lysates were incubated with beads for 3 h at room temperature. Beads were washed four times in lysis buffer before 50 μl of 2× Laemmli sample buffer was added. Phos-tag electrophoresis was performed on captured protein complexes and on input protein samples subjected to chloroform-methanol precipitation 41 . Tethering assays. The 293T cells were seeded in 24-well plates using 7.5 × 10 4 cells per well. Cells were transfected the following day using FuGENE HD and 301 ng of total plasmid. Each transfection consisted of 1 ng of phRL-SV40 (Promega), 20 ng of pGL3-Control or pGL3-BoxB, 150 ng of pcDNA3.1+ (expressing tethered or untethered proteins), and 130 ng of empty pcDNA3.1+. Cells were harvested 24 h later for luciferase activity assays using a Dual-Luciferase Reporter Assay System (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity in each well to control for variation in transfection efficiency. Biological triplicates were performed for each transfection. Rapamycin treatment of reporter cells. ANKRD52 -/-HCT116 EGFP-miR-19 cells were seeded in six-well dishes at 6 × 10 5 cells per well. The following day, cells were treated with 10, 50, or 200 nM rapamycin for 72 h (fresh medium with rapamycin was exchanged at 48 h). Cells were harvested in 2× Laemmli sample buffer at the experimental endpoint. In vitro kinase assays using immunopurified Flag-HA-AGO2. AGO2 -/cells were infected with MSCV retroviral constructs to stably express FH-AGO2 WT or FH-AGO2 5XA . FH-AGO2-expressing cells were seeded using 1.5 × 10 7 cells per dish in 15-cm dishes with three dishes per cell line. Lysates were generated using methods similar to the co-immunoprecipitation assays, with the exception that 2 ml of lysis buffer was used per dish. Lysates were diluted with one volume of lysis buffer. FH-AGO2 was immunoprecipitated using 9 μg of anti-Flag antibody (F1804, Sigma) and 150 μl of washed Dynabeads. Samples were rotated at 4 °C overnight. Beads were washed three times with lysis buffer and then treated with lambda protein phosphatase (NEB) for 45 min. Beads were washed three times with lysis buffer and then resuspended in 100 μl reaction buffer composed of 25 mM Tris-HCl (pH 7.5), 10 mM MgCl 2 , 2.5 mM DTT, 0.01% Triton X-100, 0.5 mg/ml BSA, 0.5 mM EGTA, 0.5 mM Na 3 VO 4 , 5 mM β-glycerophosphate, 170 ng of recombinant CSNK1A1 (PV3850, Thermo Fisher), and 200 μM [γ-32 P]ATP (SA = 100-500 c.p.m./pmol). Reactions were incubated at 37 °C for 2 h. Beads were separated and mixed with 50 μl of 2× Laemmli sample buffer. SDS-PAGE was performed, and gels were stained using SimplyBlue SafeStain (Invitrogen). 32 Article reSeArcH PCR amplification was performed using between 11 and 15 cycles for all samples. Paired-end sequencing was performed on a NextSeq 500 using a NextSeq 500/550 High Output v2 Kit, 75 cycle (Illumina). Mapping deep sequencing reads. Adapters were trimmed from original reads using Cutadapt (version 1.9.1) 47 with default settings. Next, the randomer sequence from the rand103Tr3 linker (Supplementary Table 8 ) was trimmed and recorded. TopHat2 (version 2.0.12) 44 was used to align mate 2 to hg38. Only the uniquely mapped reads were retained. PCR duplicates were then removed using the randomer information with an in-house script. All reads remaining after PCR duplicate removal were regarded as usable reads and used for cluster calling. eCLIP cluster calling and annotation. eCLIP clusters were identified using a previously described method 6 with the following modifications. Genome coverage by usable reads was determined at nucleotide resolution for each data set, and regions of continuous coverage greater than expected from a Poisson noise distribution were identified (P ≤ 0.001). For each region, read counts were obtained using Bedtools (version 2.17) 48 . If 50% of a read overlapped a region on the same strand, it was counted as a read covering that region. For each region, normalization to total usable reads was performed and a fold change between immunoprecipitation and input samples was calculated. Significant CLIP clusters in each data set were defined by (1) the presence of significantly greater coverage in the region than expected by chance on the basis of the Poisson distribution, and (2) log 2 (fold change) of normalized reads in the cluster was ≥2 comparing immunoprecipitation to input.
The final CLIP clusters for FH-AGO2 WT and FH-AGO2 5XA were identified by first identifying significant clusters present in both experimental replicates. A region was considered to be present in both replicates if it occurred on the same strand and the replicate clusters overlapped by at least one-third of their total length. Significant clusters from both replicates were then merged to define the final cluster length. Lastly, all clusters identified in the AGO2 -/samples were subtracted to generate the final CLIP cluster calls (Supplementary Table 7 ). Clusters were annotated on the basis of their genomic locations (Ensembl GRCh38.85) if 55% of the cluster overlapped with a given genomic region. If a cluster was assigned to multiple annotations, the annotation was selected using the following priority: CDS exon > 3′ UTR > 5′ UTR > protein-coding gene intron > noncoding RNA exon > noncoding RNA intron > intergenic. Identification of active miRNA seed families and calculation of CLIP coverage at miRNA binding sites. Active miRNAs in HCT116 were identified using an approach similar to that described previously 6 with the following modifications. The top 100 most highly expressed miRNAs in HCT116 cells were identified on the basis of a previously published small RNA sequencing experiment in this cell line 49 and collapsed to 66 7-nucleotide seed families with identical sequence from nucleotides 2-8. Eight-nucleotide binding sites for these seeds, defined as in ref. 3, were identified in the 3′ UTRs of all expressed genes (FPKM > 0) using seqMap (version 1.0.12) 50 . The locations were then transformed to genomic coordinates and extended 10 nucleotides upstream and downstream to obtain a seed match region (excluding sites on exon-exon junctions). The numbers of crosslinking sites in these seed match regions for each miRNA seed family in FH-AGO2 WT CLIP data were counted, normalized to the total usable reads in each replicate library, and averaged across replicates. To determine the significance cut-off, all possible 8-nucleotide sequences except for known miRNA seeds and those with four consecutive A, C, G, or T nucleotides were used to generate a null distribution. These background 8-nucleotide sequences were divided into 13 groups with 1,000 8-nucleotide sequences in the first 12 groups and 678 8-nucleotide sequences in the final group. CLIP crosslinking to each 8-nucleotide sequence in expressed 3′ UTRs was quantified as described above for actual miRNA seeds. An mRNA seed family was considered to be active in HCT116 cells if it obtained more crosslinking events than expected by chance, defined by the average number of crosslinking events from each of the 13 background 8-nucleotide groups above which P < 0.01. On the basis of this analysis, 15 active miRNA seed families were identified (representative miRNA: miR-423-5p, miR-17-5p, miR-200a-3p, miR-19a-3p, miR-23a-3p, miR-148a-3p, miR-221-3p, miR-125-5p, miR-182-5p, miR-21-5p, miR-30a-5p, miR-25-3p, let-7a-5p, miR-27a-3p, miR-24-3p).
To quantify CLIP coverage of miRNA binding sites in FH-AGO2 WT and FH-AGO2 5XA CLIP data (Fig. 6c ), 8-, 7-, and 6-nucleotide binding sites, defined as in ref. 3 , for all active miRNAs were identified within FH-AGO2 WT CLIP clusters in 3′ UTRs using seqMap. Clusters with only a single type of binding site (8, 7 , and 6 nucleotides) were identified. If an 8-nucleotide binding site was identified, this site was excluded from 7-or 6-nucleotide categories. Likewise, 7-nucleotide sites were excluded from the 6-nucleotide sites. Clusters were further filtered for those that were present in transcripts with FPKM > 0 in both FH-AGO2 WT and FH-AGO2 5XA cell lines, yielding 228, 89, and 80 clusters containing 6, 7, or 8 nucleotides, respectively. For each cluster with a given type of binding site, CLIP coverage was calculated by determining the average number of CLIP reads in the cluster in each replicate normalized to the total number of reads in all clusters in each replicate, divided by FPKM of the transcript. The final reported CLIP coverage is the average of both replicates.
To quantify CLIP coverage of miRNA binding sites in FH-AGO2 5XA -unique clusters versus FH-AGO2 WT /FH-AGO2 5XA -common clusters (Extended Data Fig. 10e ), 8-, 7-, and 6-nucleotide binding sites for all active miRNAs were identified within each class of CLIP cluster. Windows around each site were then extended 10 nucleotides upstream and downstream to obtain a seed match region. The numbers of crosslinking sites within these regions were counted and normalized to the total number of reads in clusters of each class (FH-AGO2 5XA -unique or FH-AGO2 WT / FH-AGO2 5XA -common) to derive the CLIP coverage used to draw the CDF plots. CLIP coverage of FH-AGO2 5XA rescued versus non-rescued transcripts. Genes whose repression in AGO2 -/cells was rescued by FH-AGO2 5XA were defined by first identifying the genes that were significantly upregulated in AGO2 -/cells compared with parental HCT116 (FDR ≤ 0.05), then, among these genes, those that were significantly downregulated in FH-AGO2 5XA versus AGO2 -/-(FDR ≤ 0.05). All other genes upregulated in AGO2 -/cells were considered not-rescued. The FH-AGO2 WT CLIP coverage for each gene in these classes was calculated as the sum of all reads in CLIP clusters in a given 3′ UTR, normalized to total reads in all clusters, divided by the FPKM of the transcript. The final reported CLIP coverage (Extended Data Fig. 10d ) is the average of both FH-AGO2 WT replicates. mRNA half-life analysis. Half-lives of transcripts with FH-AGO2 5XA CLIP clusters in their 3′ UTRs were obtained from a previously published study 38 . Genes that had half-lives assigned to more than one RefSeq mRNA isoform were removed to avoid ambiguity. Genes in the top quartile of half-lives were defined as having a long half-life (n = 273) and genes in the bottom quartile of half-lives were defined as having a short half-life (n = 274). The total numbers of CLIP reads in clusters in a given 3′ UTR were obtained for each replicate, and edgeR (version 3.8.6) 46 was used to calculate the normalized fold change of CLIP coverage comparing FH-AGO2 5XA with FH-AGO2 WT (Extended Data Fig. 10f ). Data availability. All high-throughput sequencing data generated in the course of this study (CRISPR-Cas9 screens, RNA-seq, eCLIP) have been deposited in Gene Expression Omnibus under accession number GSE89946. All other data are available from the corresponding author upon reasonable request.
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